Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Maly

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Haematology|May 6, 2016
Pembrolizumab in classical Hodgkin's lymphomaJoseph Maly, Lapo Alinari
Current Hematologic Malignancy Reports|February 20, 2016
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsJoseph Maly, James S Blachly
Leukemia & Lymphoma|August 12, 2017
Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utilityDaniel M Guidot, Jeffrey M Switchenko, Loretta J Nastoupil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, Alexander E Perl, Joseph Maly, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Future Oncology (London, England)|March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMMLGuillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
The Lancet. Haematology|December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 studyGuillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Haematology|May 6, 2016
Pembrolizumab in classical Hodgkin's lymphomaJoseph Maly, Lapo Alinari
Current Hematologic Malignancy Reports|February 20, 2016
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsJoseph Maly, James S Blachly
Leukemia & Lymphoma|August 12, 2017
Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utilityDaniel M Guidot, Jeffrey M Switchenko, Loretta J Nastoupil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, Alexander E Perl, Joseph Maly, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Future Oncology (London, England)|March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMMLGuillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
The Lancet. Haematology|December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 studyGuillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Pageof 1